• Apr 01, 2016

    Module 3 | Genotyping

    Edward J. Mayeaux, Jr, MD, Warner K, Huh, MD, Mark H. Einstein, MD, MS, Thomas C. Wright, Jr, MD
    CME 0.25 AMA PRA Category 1 Credit
    Non Member: $0.00

    Activity Summary:

    In 2009 the FDA approved the first HPV genotyping assay which identified HPV 16 /18.  Since these two HPV genotypes are found in over 70% of cervical cancers, testing for these genotypes allows HPV positive women at highest risk for invasive cancer to be identified and immediately sent to colposcopy.  In addition, high-grade cancer precursors are found in about 25% of women who have HPV 16, so this is a major risk factor for cervical disease.

    Despite the fact that 3 out of 4 FDA approved HPV tests can provide genotyping information for HPV 16/18, many clinicians do not currently ask their laboratories to provide this information.  In large part this is due to a lack of awareness around the importance of HPV 16.

     

    Audience:

    This activity is intended for clinicians from a variety of specialties including obstetrics and gynecology, family medicine and, internal medicine, for residents in obstetrics/gynecology and family medicine, for advanced practice clinicians working in family planning and other community clinics, private offices and hospital settings, for pathologists who supervise residents and fellows, and for physicians with administrative responsibility for gynecology patients.

     

    Learning Objectives:

    Upon completion of the webinar, participants will be able to:

    • Translate epidemiology of specific HPV genotypes and cervical neoplasia (both high-grade precursors and invasive cervical cancer)
    • Recognize various screening and management guidelines that utilize genotyping and their rationale
    • Identify the risk of high grade cervical disease associated with infection with HPV 16. 

    CME Information:

    ACCME Accreditation

    The American Society for Colposcopy and Cervical Pathology (ASCCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Continuing Medical Education Credits

    The American Society for Colposcopy and Cervical Pathology designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Note

    Many professions recognize AMA PRA Category 1 Credit(s)™. To claim AMA PRA Category 1 Credit(s)™ through other professions, please visit the following websites:

     

    Faculty/Disclosures:

    Edward J. Mayeaux, Jr, MD, DABFP, FAAFP
    ASCCP, President
    Professor and Chairman
    Department of Family and Preventive Medicine
    Professor of Obstetrics and Gynecology
    University of South Carolina School of Medicine
    Columbia, South Carolina

    Warner K, Huh, MD
    Professor
    Division of Gynecologic Oncology
    Department of Obstetrics and Gynecology
    University of Alabama, Birmingham
    Birmingham, Alabama

    Mark H. Einstein, MD, MS, FACS, FACOG
    Professor and Chair
    Department of Obstetrics, Gynecology and Women’s Health
    Assistant Dean, Clinical Research Unit Rutgers New Jersey Medical School

    Moderator:

    Thomas C. Wright, Jr, MD
    Past President, ASCCP
    Professor Emeritus of Pathology and Cell Biology
    Columbia University Medical Center
    New York, New York

    Management of Conflicts of Interest and Contributed Funds:

    As an accredited provider of CME credit, ASCCP is required to comply with the ACCME's Standards for Commercial Support and has implemented a management process to ensure that anyone in a position to affect the content of the educational activity (e.g., faculty, planners, etc.) disclosed all relevant financial relationships with a commercial interest and ensured that those relationships do not influence presentation materials. All faculty have agreed to base their presentations on best available evidence. ASCCP discloses to learners any financial relationship(s) to healthcare-related commercial interests existing within the past 12 months to include the following information:

    1. the name of the individual;
    2. the name of the commercial interest; and,
    3. the nature of the relationship the person has with each commercial interest.

    Slides and slide notes are reviewed for possible bias prior to the activity's release by the Accreditation Committee and peer-reviewers, and potential conflicts of interest are resolved prior to the live presentation. Any discussion of off-label use of products is noted when appropriate, as is discussion of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Disclosures of these commitments and/or relationships are published in these lecture materials and provided prior to the start of the activity, so the learners may formulate their own judgments regarding the presentation(s). Under ASCCP policy, anyone declining either to disclose or amend material to eliminate potential bias identified by the Accreditation Committee will be replaced.

    Author, Reviewers, and Planners' Disclosure Information:

    The following are all reported disclosures of interest or potential conflicts from the 12 months preceding this activity.

    • Warner K, Huh, MD, Roche (Data Steering Committee); Merck & Co, Inc. (Advisory Board)
    • Thomas C. Wright, Jr, MD, Roche (Consultant) (Speaker's Bureau); GenProbe/Hologics (Consultant) (Speaker's Bureau); Cepheid (Consultant); Inovio (Consultant)

    Those reporting no financial relationships or conflict of interest to disclose:

    • Edward J. Mayeaux, Jr, MD, DABFP, FAAFP (Speaker)
    • Mark H. Einstein, MD, MS (Speaker)
    • Jeff Andrews, MD (ASCCP Chief Medical Officer, Planner)
    • Kerry O. Curtis, (ASCCP Executive Director, Planner)
    • Patricia Cason (Education Committee, Reviewer)    
    • Colleen Stockdale, MD (Education Committee, Reviewer)
    • Jot Grammer (ASCCP Education Manager, Planner)

     

     

    Notice of Contributed Funds

    This  webinar was funded in part through an unrestricted education grant received from Roche Diagnostics. The planning and implementation of this CME activity was conducted without influence of any commercial interest.

    Statement of Independence

    This CME activity was planned and produced in accordance with the ACCME Essentials Areas and Elements and the Updated Criteria. ASCCP also states that all decisions relating to the development and production activities of each lecture were made independent of any commercial interest. The ASCCP strives to develop and present educational activities that are balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs. Please forward your recommendations to cme@asccp.org.

     

    Disclaimer

    The ASCCP Webinar Series is an educational resource and as such does not define a standard of care, nor is it intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate.

    The statements and opinions expressed within this education program are those of the authors and not necessarily those of the American Society for Colposcopy and Cervical Pathology (ASCCP). ASCCP disclaims any responsibility and/or liability for such information.

     

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.